C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) have been given an average rating of “Moderate Buy” by the seven ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $7.75.

A number of research firms have commented on CCCC. lifted their target price on C4 Therapeutics from $20.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, February 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of C4 Therapeutics in a report on Wednesday, January 21st. Wall Street Zen upgraded C4 Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, February 28th. Barclays upped their target price on shares of C4 Therapeutics from $5.00 to $7.00 and gave the company an “overweight” rating in a research note on Thursday, February 26th. Finally, TD Cowen reaffirmed a “buy” rating on shares of C4 Therapeutics in a report on Thursday, February 26th.

C4 Therapeutics Stock Performance

Shares of NASDAQ CCCC opened at $2.72 on Monday. The firm’s 50 day moving average price is $2.35 and its 200-day moving average price is $2.40. C4 Therapeutics has a 52-week low of $1.09 and a 52-week high of $3.82. The company has a market cap of $264.93 million, a PE ratio of -2.00 and a beta of 2.85.

C4 Therapeutics (NASDAQ:CCCC) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.25. C4 Therapeutics had a negative net margin of 292.08% and a negative return on equity of 53.83%. The company had revenue of $11.02 million during the quarter, compared to the consensus estimate of $4.48 million. On average, analysts forecast that C4 Therapeutics will post -1.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On C4 Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Zacks Investment Management purchased a new stake in C4 Therapeutics during the 3rd quarter valued at $29,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of C4 Therapeutics in the 2nd quarter worth $31,000. Delta Investment Management LLC purchased a new position in shares of C4 Therapeutics in the 4th quarter worth $38,000. Virtu Financial LLC bought a new stake in shares of C4 Therapeutics in the fourth quarter worth $39,000. Finally, Catalyst Funds Management Pty Ltd bought a new stake in shares of C4 Therapeutics in the second quarter worth $40,000. Institutional investors own 78.81% of the company’s stock.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.